BIO International Convention presentation

Brisbane, 8 June 2023

QBiotics Group Limited (QBiotics) is pleased to share a copy of the presentation delivered to potential partners and investors at the BIO International Convention through 5-8 June in Boston, Massachusetts, USA.

The Bio International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, it offers extensive networking and partnering opportunities, and provides insights on the major trends affecting the industry.

In the presentation Richard Godfrey, representing QBiotics in Business Development, Licensing and Partnerships, will provide an update on the Company’s human and veterinary programmes in oncology and wound healing. The presentations will include recent Phase I safety and efficacy data with tigilanol tiglate (TT) in cancer patients and details of two ongoing Phase II studies in later stage patients with Head and Neck cancer and Soft Tissue Sarcoma, being treated with TT.

Presentation details

Conference: BIO International Convention at the Boston Convention & Exhibition Center, USA
Date: 5 June 2023
Time/s: Richard Godfrey will present in Session Room 103 from 12:30-12:45 PM Easter Daylight Time (EDT).
Meetings: Any potential partners or investors interested in engaging around QBiotics and its programmes are invited to contact the Company directly or via the one-on-one conference partnering systems.

You can download the presentation and more information on the conference is available via the following link:


Dr Victoria Gordon
CEO & Managing Director, QBIOTICS GROUP or

Richard Godfrey
Business Development, Licensing and Partnering

JANE LOWE, IR DEPARTMENT or +61 411 117 774



QBiotics is an unlisted public Australian life sciences company that discovers and develops pharmaceuticals derived from nature to address unmet medical needs in humans and companion animals. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds.

QBiotics’ business model is to develop products that have applications in both veterinary and human markets. Success in the veterinary programme validates QBiotics technology and de-risks human development while having the potential to generate early revenue.

QBiotics’ lead oncology product, tigilanol tiglate, is a small molecule targeting a range of solid tumours and is currently in human clinical Phase II development. A veterinary formulation of tigilanol tiglate is registered and marketed as an oncology pharmaceutical, under the trade name STELFONTA®, in the USA, Europe, the UK and Australia.

QBiotics’ lead wound healing product is a small molecule targeting a range of wounds including chronic and acute wounds and burns. Preparation is in progress for a first-in-human Phase I/IIa clinical trial in patients with venous leg ulcers.